The aim of this study was to evaluate the possible protective effects of dapagliflozin in an experimental sepsis model in rats.
INTRODUCTION
Sepsis is defined as serious clinical syndrome which occurs as a consequence of an impaired inflammation response against infection characterized by an abnormal physiological, biological, and biochemical process. [1] According to a retrospective analysis of international databases, the global incidence rate between 1995 and 2015 was 437 out of 100,000 for sepsis and 270 out of 100,000 for severe sepsis. [2] During the management of sepsis, organ failure must be carefully evaluated because it is well established that damage to the In many studies, sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have been observed to have antioxidant effects by increasing antioxidant enzymes and reducing oxidative stress markers. Furthermore SGLT2 inhibitors have been reported to reduce inflammatory markers, suppress apoptosis in the cell and have a potential effect on cell healing. [8] [9] [10] [11] [12] A literature review revealed that dapagliflozin, a new antidiabetic agent, has not been investigated for its effects on oxidative stress, inflammation, and apoptosis in an experimental sepsis model. Therefore, the objective of this study was to investigate the antioxidant, anti-inflammatory, and antiapoptotic effects of dapagliflozin in rats in a cecal binding and puncture sepsis model.
MATERIALS AND METHODS

Experimental Animals
Sprague-Dawley rats (250-350 g) of both sexes supplied by the Experimental Animal Implementation and Research Center of Marmara University were housed in relative humidity (65-70%) and a temperature-controlled room (22±2°C) with standardized light/dark (12-hour) cycles. The rats were fed with standard rat pellets and had free access to water. This study protocol was approved by Marmara University Animal Experiments Local Ethical Committee (Ethical approval number and date: 115.2016.mar; 12.12.2016 ).
Experimental Design
The experimental sepsis model was developed using a CLP procedure. It has been established that the cecum contains a high concentration of Gram-positive and Gram-negative bacteria. This polymicrobial content spreads to the peritoneum in the CLP model and causes sepsis. The rats were randomly divided into a sham or a CLP group, each of which included subjects of both sexes. Anesthesia was provided with a combination of ketamine 100 mg/kg and xylazine 10 mg/kg. After the midline laparotomy, the cecum was gently pulled out and ligated above the ileocecal valve to maintain bowel passage, 3 perforations were made on the antimesenteric side with a 21-gauge needle, and feces expression was allowed. The sham-operated control group (n=16) underwent a laparotomy without ligature or punctures and the abdomen was closed appropriately. Data obtained from previous studies indicate that CLP-induced sepsis mortality occurs in the first 3 days. [13] The rats were decapitated 24 hours after the operation. [5, 6] The survival rate of the experimental animals was recorded throughout the process. [14] [15] [16] Four days before the CLP surgery, saline (n=8) or dapagliflozin (n=8; 10 mg/kg, 10 mL/kg; Forxiga, AstraZeneca, Cambridge, UK) was administered to the subjects in the sham and dapagliflozin groups. Orogastric gavage was performed in the dapagliflozin-treated CLP group and the sham-operated rats were injected with saline. [9, 14, 15, 17] On day 5, sepsis was induced using the CLP model and 24 hours later the rats were sacrificed. There were 4 female rats (250-300 g) and 4 male rats (300-350 g) in each group. Serum and tissue (kidney, lung, liver) samples were obtained and preserved (-80°C or 10% buffered formalin) in order to be used for further biochemical and histological analysis ( Fig. 1 ).
Biochemical Analyses Measurement of Serum Blood Urea Nitrogen, Creatinine, and Glucose
The serum blood urea nitrogen (BUN), creatinine, and glucose levels were determined using an auto analyzer according to the manufacturer's instructions (Cobas Integra 400 plus; Roche Diagnostics GmbH, Risch-Rotkreuz, Switzerland).
Measurement of Malondialdehyde and Glutathione
The level of malondialdehyde (MDA), a byproduct of lipid peroxidation, was measured based on thiobarbituric acid reactive substance formation in kidney, lung, and liver tissues. [18] Tissue samples were homogenized in 10% trichloroacetic acid solution using 10-fold dilutions. The homogenized tissue samples were then centrifuged at 2000 g for 15 minutes at 4°C; the supernatant was removed and re-centrifuged at 41,400 g for 8 minutes. The upper organic liquid layer was separated and was measured with a spectrophotometer (Epoch; BioTek Instruments, Inc., Winooski, VT, USA) at 532 nm. Thiobarbituric acid reactive substance formation was measured [19] and the lipid peroxidation measurement was provided in terms of MDA equivalents using an extinction coefficient of 1.56×105 M −1 cm −1 and expressed as nmoL MDA/g tissue.
GSH levels were measured in kidney, lung, and liver tissues according to the method developed by Beutler [20] using a modification of the Ellman procedure. The experimental principle is to measure the colored product resulting from the reaction of the sulphydryl groups with 5-5 'dithiobis 1-2 nitrobenzoic acid in the spectrophotometer at 412 nm. The results were expressed as µmol GSH/g tissue.
Measurement of Myeloperoxidase Activity
Myeloperoxidase (MPO) is a member of the peroxidase family. MPO activity in the lysates of kidney, lung, and liver tissues was assessed using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Catalog No: LS-F4305, Lot No: 103692; LifeSpan BioSciences, Inc., Seattle, WA, USA). The results were measured as U/g tissue.
Measurement of Interleukin 1 Beta and Tumor Necrosis Factor-Alpha
Interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) levels were measured in all tissues (kidney, lung, liver) with commercial ELISA kits ( 
Measurement of Tissue Caspase 8 and Caspase 9
The kidney, lung, and liver lysates were analyzed to determine caspase 8 and 9 levels with a commercial kit (Catalog No: APT171, Lot No: 2829013; Cat. No: APT173, Lot No: 2841705, respectively; MilliporeSigma, Burlington, MA, USA). The p-nitroaniline absorbance in non-apoptotic specimens and apoptotic specimens was compared and the caspase 8 and 9 activity was calculated as fold increase.
Histological Evaluation
The samples obtained from kidney, liver, and lung tissues were fixed in 10% neutral buffered formalin for 48 hours and then examined with routine histological processing. Approximately 4 µm-thick paraffin sections were stained with hematoxylin and eosin. Periodic acid-Schiff staining was applied to assess the basal membrane and proximal tubules of kidney samples. The sections were examined and photographed using a light microscope (BX51; Olympus Corp., Tokyo, Japan) attached to a digital camera (DP72; Olympus Corp., Tokyo, Japan). Histologists evaluated the glomerular structure and Bowman's capsule, proximal and distal tubules, interstitial bleeding, and vascular congestion in kidney tissue; damaged hepatocytes with vacuoles and pyknotic nuclei, sinusoidal congestion, and increase of activated Kupffer cells in liver tissue; and alveolar morphology, interstitial bleeding, and vascular congestion in lung tissue.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc. La Jolla, CA, USA). All data are expressed as mean±SEM. Relationships within groups were measured using one-way analysis of variance followed by Tukey's post hoc test. P<0.05 was considered statistically significant. The odds ratio (OR) was calculated based on a chisquare test for survival rate.
RESULTS
Survival Rate
The 24-hour survival rate was 75% (6/8 rats) in the salinetreated CLP group, whereas the survival rate was 100% for the other groups. There was no statistically significant difference in survival between the dapagliflozin-treated CLP group and the saline-treated CLP group (OR: 0.75, 95% confidence interval [CI]: 0.50-1.12; p>0.05).
Blood Urea Nitrogen, Creatinine and Glucose Levels
The CLP surgery groups developed kidney dysfunction and had higher plasma BUN (p<0.01) and creatinine (p<0.01-0.001) levels in comparison with the saline-treated sham group (Fig. 2 ).
The glucose level was significantly higher in the dapagliflozintreated sham group compared with the saline-treated sham group (p<0.05). A significant decrease was observed in the saline-treated CLP group when it was compared with the saline-treated sham group (p<0.01) ( Fig. 2c ). The MDA level in all tissues was significantly elevated in the saline-treated CLP group when compared with the salinetreated sham group (p<0.05-0.01; Fig. 3 ). The MDA level in the dapagliflozin-treated CLP group was significantly lower in all tissues than that of the saline-treated CLP group (p<0.05-0.01; Fig. 3 ). Interestingly, the MDA level in the dapagliflozintreated sham group was significantly higher in kidney tissue than that of the saline-treated sham group (p<0.05) (Fig. 3a) .
The GSH level was significantly lower in the kidney and hepatic tissue of the saline-treated CLP group when compared with the saline-treated sham group (p<0.050-001; Fig. 3b and f ), while an increase in GSH in kidney tissue was observed with administration of dapagliflozin (p<0.001, Fig. 3 ).
Myeloperoxidase, Tumor Necrosis Factor Alpha, and Interleukin 1 Beta Levels
MPO activity was found to be significantly high in all of the tissue samples of the saline-treated CLP group when compared with the saline-treated sham group (p<0.01-0.001; Fig. 4 ). CLP-induced elevation in MPO activity were only significantly decreased in renal tissue in the dapagliflozin-treatment group (p<0.05; Fig. 4 ).
TNF-α and IL-1β levels demonstrated a statistically significant increase in the saline-treated CLP group when compared with the saline-treated sham group in lung and liver tissues (p<0.05-0.001). Administration of dapagliflozin significantly diminished these alterations in the saline-treated CLP group (p<0.01-0.001; Fig. 4 ).
Caspase 8 and 9
In the saline-treated CLP group, caspase-8 and 9 activity in kidney, lung, and liver tissues was significantly greater when compared with the saline-treated sham group (p<0.01-0.001; Fig. 5 ). Dapagliflozin administration did not alleviate CLP-induced apoptosis and there was a significant increase (p<0.001) in caspase-8 activity in kidney tissue samples when compared with the saline-treated CLP group.
Histological Evaluation
Regular morphology of the interstitial space, Bowman's space and glomeruli, proximal and distal tubules were seen in kidney tissues obtained from the saline-treated sham and dapagliflozin-treated sham groups (Fig. 6a, b ). In the saline-treated CLP group, interstitial bleeding, glomerular congestion, significant dilation of Bowman's space, and tubular degeneration were observed ( Fig. 6c ). Regression in the dilation of Bowman's space, tubular degeneration, moderate glomerular congestion, mild interstitial bleeding, and vascular congestion were observed in the dapagliflozin-treated CLP group (Fig. 6d ).
Regular parenchyma morphology was also seen in liver tissue collected from the saline and dapagliflozin treated sham groups (Fig. 7a, b (Fig. 7c ). Sinusoidal congestion, and degenerated hepatocytes and activated Kupffer cells were reduced in the dapagliflozintreated CLP group (Fig. 7d ).
Regular parenchyma morphology was viewed in lung tissue obtained from the saline-treated sham and dapagliflozin-treated sham groups (Fig. 8a, b ). Severe interstitial bleed-ing and vascular congestion, cellular debris in the alveolar lu-men, and degenerated alveolar structures were observed in the salinetreated CLP group (Fig. 8c ). Moderate interstitial bleeding and vascular congestion, partial degeneration of alveolar structures, cellular debris in the lumen of a number of alveoli, and in some regions, alveoli with regular morphology were seen in the dapagliflozin-treated CLP group (Fig. 8d ).
DISCUSSION
Dapagliflozin reduced oxidative stress (MDA) and inflamma-tion (MPO), but conversely, increased the level of antioxidants (GSH) in the kidney. Recovery of histological features of renal injury was demonstrated. In addition, dapagliflozin treatment decreased oxidative stress (MDA) and inflammation (TNF-α) in lung tissue. A slight recovery in the histological features of lung injury was noted. Additionally, dapagliflozin treatment lowered inflammation (TNF-α, IL-1β), but there was only a limited decrease in the level of oxidative stress in the liver. A slight recovery in the histological features of liver injury was observed.
Immune system function declines with diabetes mellitus. This altered immune response can lead to the progression toward sepsis through the growth of microorganisms. In experimental animal models and diabetic human studies, deficiencies in immunoreactivity have been shown to increase susceptibility to sepsis and other infections. In patients with Type 1 diabetes, sepsis patients and sepsis can be a common consequence in diabetic patients. Therefore, new treatments are needed. [21] Dapagliflozin, a new drug used in the treatment of diabetes, is an inhibitor of SGLT2. [9] A review of the literature did not reveal any studies of dapagliflozin and sepsis as yet. However, consistent with the results of the present study, it has been reported that dapagliflozin (10 mg/kg/day) decreased BUN and creatinin levels in a renal ischemic reperfusion model in rats and had a protective effect on renal tubular cells. [9] In addition, it has been shown that dapagliflozin reduced apoptotic cell death by inducing hypoxia inducible factor 1 in ischemic renal tissue and ischemic tubular cell cultures and decreasing Bax/BcL2 ratio and terminal dUTP nick-end labeling-positive cells. [9] Depending on the characteristics of a critical illness (sepsis, burns, etc.), acute hyperglycemia and insulin resistance can develop even if there is no history of diabetes mellitus in the patient. This condition has been assessed as a stress response.
The development of this response may involve the release of inflammatory cytokines such as TNF-α and IL-6; an increase in stress hormones, such as cortisol; and the use of drugs such as corticosteroids. In the case of sepsis or septic shock, hyperglycemia occurs at an early stage and hypoglycemia has a late stage development. [22, 23] In our study, the decrease in blood glucose levels in the sepsis group when compared with the control suggests late-stage sepsis. In a study of mice using a sepsis model (CLP), it was demonstrated that blood glucose levels decreased in the sepsis group and that the glucose levels increased in the group given pioglitazone, which is also an anti-diabetic agent. [24] In our study, there was a decrease in blood glucose levels in the CLP group, consistent with other research available in the literature. [23] [24] [25] [26] [27] In the present study, although glucose levels were significantly increased in the dapagliflozin-treated sham group, there was no significant change in the glucose levels of the dapagliflozin-treated CLP group. Therefore, the positive findings of the current study do not suggest that dapagliflozin makes a strong contribution to glucose control.
In CLP studies performed on rats, serum TNF-α, IL-6, BUN, and creatinine levels were higher in the sepsis group compared with the control group. Increases in MDA and MPO values, a decrease in GSH values, and an increase in apoptosis were observed in the kidney, and histological examination showed renal tissue damage. [28] [29] [30] [31] [32] [33] [34] Similar findings were obtained in the sepsis model applied in our study. It was determined that there was no significant difference in the serum creatinine value between the groups, but a significant increase was noted in the CLP group after 72 hours. In addition, oxidative stress parameters and apoptotic (caspase 3) values were greater in the CLP group compared with the controls and more tissue damage was determined in the kidney and lung tissue in the histological examination. [35] Serum BUN and creatinine values in our study were consistent with the findings of sepsis (CLP method) in the literature. [8, 35] In another study, TNF-α, IL-1β, IL-6, MDA, and MPO levels of lung tissue were greater in the sepsis group compared with the control group. GSH levels were lower. [28, [36] [37] [38] [39] [40] In the histopathological evaluation, severe tissue damage was reported. [38] These results are also consistent with the findings we obtained in our sepsis model. It has also been reported that there were increases in the levels of caspase 3 and Bax/BcL 2 in the lungs. [40] The MDA level in liver tissue was elevated, whereas the GSH level decreased in the sepsis group compared with the controls. [31, 39] These results are consistent with our sepsis model. In another study, rats were evaluated 24 hours after CLP, and when the sepsis group was compared with the control group, the MDA level was significantly higher in the liver tissue, but there was no increase in the kidney or lung tissues. MPO values increased in the lung; however, there was no significant difference in the liver or kidney tissues. In the same study, plasma cytokines (TNF-α, IL-1β, etc.), BUN, and creatinine levels were greater in the CLP group, and there was no significant decline in glucose levels. [25] Other research indicated that there was an increase in kidney MPO values as well as MDA values in kidney and liver tissue, but there was no significant different in liver MPO level. [41] The effect of long-term use of dapagliflozin on glucose homeostasis and diabetic nephropathy has previously been investigated. Dapagliflozin has improved hyperglycemia and albuminuria, depending on the dose (0.1-1.0 mg/kg), and reduced macrophage infiltration, gene expression of inflammatory cytokines, and oxidative stress in diabetic mice. There was Figure 8 . Representative photomicrographs of lung tissue in the experimental groups. Lung parenchyma with regular morphology in the saline-treated sham (a) and dapagliflozin-treated sham (b) groups and severe interstitial bleeding (*) and vascular congestion, degeneration in alveolar structure (arrow) in the saline-treated cecal ligation and puncture (CLP) group (c) with mild interstitial bleeding (*) and vascular congestion, partly degeneration of alveolar structure (arrow), and regular alveolar morphology (arrow, inset) in the dapagliflozintreated CLP group in some places (d). H&E staining, scale bars: 50 µm (x20).
(a) (b) (c) (d) no significant difference in BUN or serum creatinine levels. [8] These results are consistent with those of our study. Other researchers found that dapagliflozin reduced oxidative stress and apoptosis induced by high glucose in type 1 diabetic mice, alleviated diabetic nephropathy, and reduced macrophage infiltration. [42] In another study, the effect of SGLT inhibition on polycystic kidney dysfunction was investigated in rats. Dapagliflozin (10 mg/kg) was found to unexpectedly cause an increase in cyst volume with albuminuria, hyperfiltration, and polycystic kidney failure in rats. [43] Additional studies should be conducted to develop new alternatives for prophylactic treatment of sepsis and to investigate the different effects of this new medicine, dapagliflozin.
The results of our study suggest that diabetic patients using dapagliflozin may also benefit from the effect on oxidative stress. As a result, the findings of this study highlighted a possible protective effect of dapagliflozin in renal damage. Dapagliflozin also slightly alleviated lung and liver injury.
